Advanced Filters
noise

Carcinoma Clinical Trials

A listing of Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6,070 clinical trials
Y Yasir Alayed, MD

Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer

Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 30 Gy in 5 fractions, once weekly to the pelvis in post operative patients with endometrial cancer.

18 - 99 years of age Female Phase 2
M Mingyue Cai, Dr.

DEB-TACE+HAIC vs. HAIC for Large HCC

This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large hepatocellular carcinoma (HCC).

18 - 75 years of age All Phase 3
P Pamela Soliman, MD

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied

18 years of age Female Phase 1
S Site Public Contact

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will …

18 years of age Female Phase N/A

Neoadjuvant Therapy of HAIC(GEMOX) Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors:NEO-ERA-01 Study

Clinical Study on the efficacy and safety of hepatic arterial perfusion chemotherapy and Renvastinib combined with Adebrelimab neoadjuvant therapy for resection of high-risk biliary tract carcinoma.

18 - 75 years of age All Phase 2
J Jason Robinson, PHD

Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer

This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators of the potential risks and benefits of switching …

50 - 80 years of age All Phase N/A
C Cornelis G Gerestein, MD, PhD

Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer

This pilot study evaluates the feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with endometrial cancer.

18 years of age Female Phase 3

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order …

18 years of age Female Phase 1/2
Y Yevgeniy Vinogradskiy, MD

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung Cancer, EUCLID Trial

This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung cancer. As part of the treatment for lung cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, …

18 years of age All Phase N/A
K Koen Brummel, Drs.

Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer

The goal of this clinical trial is to establish the fraction of patients that achieve a major pathological response (MPR) after 9 cycles of pembrolizumab, with the ultimate aim of informing a follow-up randomized trial. Participants will receive 9 cycles of pembrolizumab before their standard of care hysterectomy.

18 years of age Female Phase 2

Simplify language using AI